We are live on ! Find out more
TCRX icon

TScan Therapeutics
TCRX

80 hedge funds and large institutions have $242M invested in TScan Therapeutics in 2024 Q2 according to their latest regulatory filings, with 31 funds opening new positions, 19 increasing their positions, 14 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

94% more first-time investments, than exits

New positions opened: 31 | Existing positions closed: 16

36% more repeat investments, than reductions

Existing positions increased: 19 | Existing positions reduced: 14

21% more funds holding

Funds holding: 66 → 80 (+14)

6.67% more ownership

Funds ownership: 78.64% → 85.31% (+6.7%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

11% less capital invested

Capital invested by funds: $272M → $242M (-$29.9M)

Holders
80
Holders Change
+14
Holders Change %
+21.21%
% of All Funds
1.16%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
31
Increased
19
Reduced
14
Closed
16
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$21.8M
2
GPP
Great Point Partners
Connecticut
+$7.41M
3
SC
Stempoint Capital
New York
+$6.66M
4
LP
LMR Partners
United Kingdom
+$5.24M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$3.94M

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$2.87M
2
LCM
Laurion Capital Management
New York
-$2.38M
3
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.37M
4
Goldman Sachs
Goldman Sachs
New York
-$1.77M
5
Citigroup
Citigroup
New York
-$854K
Name Holding Trade Value Shares
Change 		Change in
Stake
California State Teachers Retirement System (CalSTRS)
76
California State Teachers Retirement System (CalSTRS)
California
$16.3K +$21.9K +2,782 New
AB
77
Amalgamated Bank
New York
$8K +$10.5K +1,329 New
ACA
78
Atlas Capital Advisors
Wyoming
$105 – – –
Susquehanna International Group
79
Susquehanna International Group
Pennsylvania
– -$2.37M -297,902 Closed
CSS
80
Cubist Systematic Strategies
Connecticut
– -$352K -44,308 Closed
Balyasny Asset Management
81
Balyasny Asset Management
Illinois
– -$333K -41,942 Closed
Two Sigma Investments
82
Two Sigma Investments
New York
– -$300K -37,747 Closed
ECM
83
ExodusPoint Capital Management
New York
– -$283K -35,661 Closed
HF
84
HRT Financial
New York
– -$276K -34,789 Closed
BHCM
85
Brevan Howard Capital Management
Jersey
– -$275K -34,578 Closed
YIH
86
Y-Intercept (HK)
Hong Kong
– -$194K -24,446 Closed
PAS
87
Point72 Asia (Singapore)
Singapore
– -$157K -19,736 Closed
CGIM
88
Cannon Global Investment Management
Florida
– -$139K -17,500 Closed
OAC
89
OMERS Administration Corp
Ontario, Canada
– -$113K -14,200 Closed
JFG
90
Jefferies Financial Group
New York
– -$96.9K -12,200 Closed
CAS
91
CTC Alternative Strategies
Illinois
– -$87.3K -11,000 Closed
Cambridge Investment Research Advisors
92
Cambridge Investment Research Advisors
Iowa
– -$80K -10,061 Closed
Lazard Asset Management
93
Lazard Asset Management
New York
– -$18.7K -2,375 -93%
Macquarie Group
94
Macquarie Group
Australia
– -$13 -1,618 Closed
Federated Hermes
95
Federated Hermes
Pennsylvania
– -$445 -56 Closed
T. Rowe Price Associates
96
T. Rowe Price Associates
Maryland
– +$96.9K +12,301 New
1 2 3
4

TCRX Hedge Fund Activity: Q2 2024 in Review

80 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in TScan Therapeutics (TCRX) for Q2 2024, worth a combined $242M — down 11% from $272M a quarter earlier.

Buyers outnumbered sellers: 31 funds opened new TCRX positions and 16 closed out — a net gain of 15 holders — while 19 added to existing stakes and 14 trimmed.

The largest buyer was BlackRock, adding an estimated $21.8M. The largest seller was Millennium Management, cutting an estimated $2.87M.

  • 80 institutional investors held TScan Therapeutics (TCRX) as of Q2 2024, up from 66 in Q1 2024.
  • Funds reported $242M of TScan Therapeutics stock for Q2 2024, down 11% quarter-over-quarter.
  • 31 funds opened new TScan Therapeutics positions in Q2 2024 and 16 closed out, a net change of +15 holders.
  • The largest TScan Therapeutics buyer in Q2 2024 was BlackRock, an estimated $21.8M added.
  • The largest TScan Therapeutics seller in Q2 2024 was Millennium Management, an estimated $2.87M sold.

Based on aggregated 13F filings for Q2 2024.